1 / 66

Chronic Kidney Disease and Mineral and Bone Disorder: Phosphate Binder Usage and Serum Calcium and Phosphate Levels

This report examines the usage of phosphate binders in patients with chronic kidney disease (CKD) and analyzes the distribution of serum calcium and phosphate levels. The data shows variations in medication usage and mineral metabolism among HD and PD patients.

colleenw
Download Presentation

Chronic Kidney Disease and Mineral and Bone Disorder: Phosphate Binder Usage and Serum Calcium and Phosphate Levels

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHAPTER 9:Chronic Kidney Disease – Mineral and Bone DisorderKok Lai SunChing Chen HuaFan Kin SingRozina GhazalliLiew Yew Fong Source: 21st MDTR Report 2013, NRR

  2. Table 9.1.1: Phosphate Binder in HD patients, 2004-2013 Source: 21st MDTR Report 2013, NRR

  3. Table 9.1.2: Phosphate Binder in PD patients, 2004-2013 Source: 21st MDTR Report 2013, NRR

  4. Table 9.1.3: Phosphate Binders by Sector in HD patients Source: 21st MDTR Report 2013, NRR

  5. Table 9.2.1: Distribution of corrected serum calcium, HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  6. Figure 9.2.1: Cumulative distribution of corrected serum calcium, HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  7. Table 9.2.2: Distribution of corrected serum calcium, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  8. Figure 9.2.2: Cumulative distribution of corrected serum calcium, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  9. Table 9.2.3: Distribution of serum phosphate, HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  10. Figure 9.2.3: Cumulative distribution of serum phosphate, HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  11. Table 9.2.4: Distribution of serum phosphate, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  12. Figure 9.2.4: Cumulative distribution of serum phosphate, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  13. Table 9.2.5: Distribution of corrected calcium x phosphate product, HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  14. Figure 9.2.5: Cumulative distribution of corrected calcium x phosphate product, HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  15. Table 9.2.6: Distribution of corrected calcium x phosphate product, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  16. Figure 9.2.6: Cumulative distribution of corrected calcium x phosphate product, PD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  17. Table 9.2.7(a): Variation in corrected median serum calcium level among HD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  18. Figure 9.2.7(a): Variation in median serum calcium among HD patients, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  19. Table 9.2.8(a): Variation in corrected median serum calcium level among PD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  20. Figure 9.2.8(a): Variation in median serum calcium level among PD patients, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  21. Table 9.2.7(b): Proportion of patients with serum calcium 2.1 to 2.37 mmol/L, HD centres, 2004-2013 Source: 21st MDTR Report 2013, NRR

  22. Figure 9.2.7(b): Variation in proportion of patients with serum calcium 2.1 to 2.37 mmol/L, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  23. Table 9.2.8(b): Proportion of patients with serum calcium 2.1 to 2.37 mmol/L, PD centres Source: 21st MDTR Report 2013, NRR

  24. Figure 9.2.8(b): Variation in proportion of patients with serum calcium 2.1 to 2.37 mmol/L, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  25. Table 9.2.9(a): Variation in median serum phosphate level among HD centres, 2004-2013 Source: 21st MDTR Report 2013, NRR

  26. Figure 9.2.9(a): Variation in median serum phosphate level among HD patients, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  27. Table 9.2.10(a): Variation in median serum phosphate levels among PD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  28. Figure 9.2.10(a): Variation in median serum phosphate level among PD patients, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  29. Table 9.2.9(b): Proportion of patients with serum phosphate 1.13-1.78 mmol/L, HD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  30. Figure 9.2.9(b): Variation in proportion of patients with serum phosphate 1.13-1.78 mmol/L, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  31. Table 9.2.10(b): Proportion of patients with serum phosphate 1.13-1.78 mmol/L, PD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  32. Figure 9.2.10(b): Variation in proportion of patients with serum phosphate 1.13-1.78 mmol/L, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  33. Table 9.2.9(c): Proportion of patients with serum phosphate 0.8-1.3 mmol/L, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  34. Figure 9.2.9(c): Variation in proportion of patients with serum phosphate 0.8-1.3 mmol/L, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  35. Table 9.2.10(c): Proportion of patients with serum phosphate 0.8-1.3 mmol/L, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  36. Figure 9.2.10(c): Variation in proportion of patients with serum phosphate 0.8-1.3 mmol/L, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  37. Table 9.2.11(a): Variation in corrected median calcium x phosphate product HD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  38. Figure 9.2.11(a): Variation in median corrected calcium x phosphate product among HD patients, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  39. Table 9.2.12(a): Variation in corrected median calcium x phosphate product PD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  40. Figure 9.2.12(a): Variation in median corrected calcium x phosphate product among PD patients, PD centres 2013 Source: 21st MDTR Report 2013, NRR

  41. Table 9.2.11(b): Proportion of patients with corrected calcium x phosphate <4.5 mmol2/L2, HD centres 2004-2013 Source: 21st MDTR Report 2013, NRR

  42. Figure 9.2.11(b): Variation in proportion of patients with corrected calcium x phosphate product <4.5 mmol2/L2, HD centres 2013 Source: 21st MDTR Report 2013, NRR

  43. Table 9.2.12(b): Proportion of patients with corrected calcium x phosphate <4.5 mmol2/L2, PD 2004-2013 Source: 21st MDTR Report 2013, NRR

  44. Figure 9.2.12(b): Variation in proportion of patients with corrected calcium x phosphate product <4.5 mmol2/L2, PD centres, 2013 Source: 21st MDTR Report 2013, NRR

  45. Table 9.3.1(a): Treatment of hyperparathyroidism in HD patients, 2004-2013 Source: 21st MDTR Report 2013, NRR

  46. Table 9.3.1(b): Treatment of hyperparathyroidism in PD patients, 2004-2013 Source: 21st MDTR Report 2013, NRR

  47. Table 9.3.2(a): Distribution of iPTH, HD patient 2004-2013 Source: 21st MDTR Report 2013, NRR

  48. Figure 9.3.2(a): Cumulative distribution of iPTH, HD 2004-2013 Source: 21st MDTR Report 2013, NRR

  49. Table 9.3.2(b): Distribution of iPTH, diabetic HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

  50. Figure 9.3.2(b): Cumulative distribution of iPTH, diabetic HD patients 2004-2013 Source: 21st MDTR Report 2013, NRR

More Related